Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
ProPhase Labs, Inc. is a U.S.-based diversified health and diagnostics company operating primarily in the consumer health, dietary supplements, and clinical diagnostics industries. The company focuses on developing, manufacturing, and marketing over-the-counter health products while also operating laboratory services that support clinical testing and precision medicine. Its business model combines branded consumer products with service-based diagnostic revenue streams.
Historically, ProPhase Labs built its reputation around cold remedy and immune-support products, most notably its flagship dietary supplement brand. Over time, the company expanded beyond consumer health into diagnostics and genomics-related services, reflecting a strategic shift toward higher-growth healthcare services. This evolution has been driven by acquisitions, internal expansion, and the monetization of laboratory infrastructure developed during the COVID-19 testing period.
Business Operations
ProPhase Labs operates through multiple business segments, primarily Consumer Products and Diagnostic Services, each contributing distinct revenue streams. The Consumer Products segment includes the development and sale of branded dietary supplements and functional health products sold through mass retail, e-commerce, and direct-to-consumer channels. This segment has historically generated recurring revenue and brand recognition for the company.
The Diagnostic Services segment operates through ProPhase Diagnostics, Inc., which provides clinical testing, molecular diagnostics, and laboratory services. These operations include high-complexity CLIA-certified laboratories and support services for physicians, healthcare providers, and research clients. The company also maintains ownership interests in genomic testing and data-related assets, leveraging laboratory capabilities and proprietary infrastructure developed through prior testing programs.
Strategic Position & Investments
ProPhase Labs’ strategy centers on balancing stable consumer health cash flows with scalable diagnostics and genomics opportunities. Growth initiatives have included expanding laboratory capacity, commercializing diagnostic services beyond pandemic-related testing, and exploring precision medicine and data-driven healthcare applications. The company has emphasized monetization of lab assets through diversified clinical and research-based testing services.
Key investments and subsidiaries include ProPhase Diagnostics, Inc. and Nebula Genomics, the latter focusing on consumer genomic sequencing and data ownership models. These investments position the company in emerging healthcare sectors such as personalized medicine, large-scale genomic analysis, and healthcare data monetization. Management has stated that capital allocation decisions prioritize businesses with long-term margin expansion and differentiated healthcare capabilities.
Geographic Footprint
ProPhase Labs is headquartered in the United States, with its primary corporate offices in New York. Its consumer products are sold predominantly across North America, supported by national retail distribution and online platforms. Laboratory and diagnostic operations are also U.S.-based, serving domestic healthcare providers and institutional clients.
While the company does not operate large-scale international manufacturing or laboratory facilities, it maintains global relevance through genomic data initiatives and technology platforms with international consumer reach. Its international exposure is primarily indirect, driven by digital services, partnerships, and global data participation rather than physical overseas operations.
Leadership & Governance
ProPhase Labs is led by a management team with experience in consumer health, pharmaceuticals, diagnostics, and corporate finance. The leadership philosophy emphasizes operational flexibility, asset monetization, and strategic diversification across healthcare verticals. Governance practices align with public company standards, with oversight from an independent board of directors.
Key executives include:
- Ted Karkus – Chief Executive Officer
- Ted Karkus – Chairman of the Board
- Monica Brady – Chief Financial Officer
- Ryan Keeler – Chief Operating Officer
- Drew Sutton – President, Diagnostic Services
The executive team has played a central role in transitioning the company from a single-product consumer health company into a diversified healthcare platform with laboratory and genomic capabilities.